Prosecution Insights
Last updated: November 20, 2026
Application No. 18/587,187

PROCESS OF MAKING SOMATOSTATIN MODULATORS

Final Rejection §102§DOUBLEPATENT
Filed
Feb 26, 2024
Priority
Jan 17, 2018 — provisional 62/618,538 +4 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Crinetics Pharmaceuticals Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
846 granted / 1145 resolved
+13.9% vs TC avg
Strong +31% interview lift
Without
With
+31.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
68 currently pending
Career history
1201
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
49.7%
+9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1145 resolved cases

Office Action

§102 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 67-86 are pending in the instant application. Claims 81-86 are new claims and drawn to the originally presented subject matter. An action on the merits of claims 67-86 is contained herein. Information Disclosure Statement The examiner has considered the information disclosure statements filed most recently of record. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 7/9/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 10/8/2026. Status of Rejections Double Patenting The rejection of claims 67-80 is maintained with respect to U.S. Patents No. 11,414,397, 10,597,377, and 10,875,839. Applicant’s arguments, see Remarks, filed 10/8/2026, with respect to the rejection set forth in the Non-Final Office Action mailed 7/9/2026, have been fully considered but are not found persuasive. To reiterate the rejections of record, claims 67-80 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 11,414,397. Although the claims at issue are not identical, they are not patentably distinct from each other because the instantly claimed compounds are disclosed in U.S. Patent No. ‘397 (see col. 343, claim 17, example 2-2, col. 243, lines 33-41 for HCl salt) and its method of use as recited in the instant claims (see col. 9, lines 30-40). Claims 67-80 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 10,597,377. Although the claims at issue are not identical, they are not patentably distinct for the reasons set forth in U.S. Patent No. 11,414,397 (more particularly the suggestion of employing the HCl salt in the claimed method). Claims 67-80 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 10,875,839. Although the claims at issue are not identical, they are not patentably distinct for the reasons set forth in U.S. Patent No. 11,414,397 (more particularly the suggestion of employing the HCl salt in the claimed method). Applicants argue that since the patents do not disclose the recited “monohydrochloride” salt as recited in the instant claims for the method of use but the “dihydrochloride” salt (see example 2-2 of patent ‘397 for example where the preparation method is different from what is taught in the instant application); the claims are patentably distinct. The examiner respectfully disagrees. As stated previously when analyzing U.S. Patent No. ‘397 as an example, the instantly claimed compound is disclosed (see col. 343, claim 17, example 2-2, col. 243, lines 33-41 for HCl salt) and its method of use as recited in the instant claims (see col. 9, lines 30-40). Specifically when examining the suggested limited number of salts disclosed at col. 243, hydrochloric acids are explicitly recited (see below and lines 5-10): PNG media_image1.png 198 452 media_image1.png Greyscale . The reference does teach a working example at example 2-2 as Applicant has described as a “dihydrochloride” salt. However the language at col. 243 includes all (including the claimed monohydrochloride) HCl salts of the claimed compound and is not limited to the working example. In terms of anticipation, the patent is viewed as a genus of preferred compounds (in this case HCl salts) and can anticipate a species if it can be “at once envisaged” from the disclosure by one skilled in the art (see MPEP 2131.02): III. A GENERIC DISCLOSURE WILL ANTICIPATE A CLAIMED SPECIES COVERED BY THAT DISCLOSURE WHEN THE SPECIES CAN BE "AT ONCE ENVISAGED" FROM THE DISCLOSURE "[W]hether a generic disclosure necessarily anticipates everything within the genus … depends on the factual aspects of the specific disclosure and the particular products at issue." Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1083, 89 USPQ2d 1370, 1375 (Fed. Cir. 2008). See also Osram Sylvania Inc. v. American Induction Tech. Inc., 701 F.3d 698, 706, 105 USPQ2d 1368, 1374 (Fed. Cir. 2012) ("how one of ordinary skill in the art would understand the relative size of a genus or species in a particular technology is of critical importance"). A reference disclosure can anticipate a claim when the reference describes the limitations but "'d[oes] not expressly spell out' the limitations as arranged or combined as in the claim, if a person of skill in the art, reading the reference, would ‘at once envisage’ the claimed arrangement or combination." Kennametal, Inc. v. Ingersoll Cutting Tool Co., 780 F.3d 1376, 1381, 114 USPQ2d 1250, 1254 (Fed. Cir. 2015) (quoting In re Petering, 301 F.2d 676, 681(CCPA 1962)). In Kennametal, the challenged claim was to a cutting tool requiring a ruthenium binding agent with a physical vapor deposition (PVD) coating. The reference described all the elements of the claimed coated cutting tool but did not explicitly disclose the specific combination of ruthenium binding agent with a PVD coating. However, the reference disclosed that ruthenium was one of five specified binding agents and PVD was one of three suitable coating techniques. The Federal Circuit stated that the reference’s "express ‘contemplat[ion]’ of PVD coatings provided sufficient evidence that a reasonable mind could find that a person of skill in the art… would immediately envisage applying a PVD coating. Thus, substantial evidence supports the Board's conclusion that [the reference] effectively teaches 15 combinations, of which one anticipates pending claim 1. Though it is true that there is no evidence in [the reference] of ‘actual performance’ of combining the ruthenium binder and PVD coatings, this is not required." Kennametal, 780 F.3d at 1383, 114 USPQ2d at 1255 (citations omitted). See also Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., 851 F.3d 1270, 1274, 122 USPQ2d 1116, 1120 (Fed. Cir. 2017) ("Kennametal does not stand for the proposition that a reference missing a limitation can anticipate a claim if a skilled artisan viewing the reference would "at once envisage" the missing limitation. Rather, Kennametal addresses whether the disclosure of a limited number of combination possibilities discloses one of the possible combinations.").[AltContent: rect]. Again, the document teaches a limited number of salts including HCl salts disclosed at col. 243 and one skilled in the art would have readily envisaged the claimed compound (monohydrochloride and even other HCl salts due to the limited genus to select from) and its use in treating acromegaly. Applicant’s arguments suggesting “unique and beneficial properties” is not enough to obviate the anticipatory type ODP since the fact pattern is not centered around obviousness. Thus the rejection is maintained. Status of Rejections 35 USC § 102(a)(2) The rejection of claims 67-80 is maintained. Applicant’s arguments, see Remarks, filed 10/8/2026, with respect to the rejection set forth in the Non-Final Office Action mailed 7/9/2026, have been fully considered but are not found persuasive for the reasons stated above in the maintained ODP rejection above referencing U.S. Patent No. 11,414,397. New Objections and Rejections Claim Objections Applicant is advised that should claims 68-70 and 75-77 be found allowable, claims 81-83 and 84-86 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). For example, claims 68-70 and 81-83 are limited to a method of treating acromegaly using the recited compound specifically (same is true for claims 75-77 and 84-86 which include compositions thereof). Thus the scope of these claims are identical and duplicative. Correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 81-86 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 11,414,397. Although the claims at issue are not identical, they are not patentably distinct from each other because the instantly claimed compounds are disclosed in U.S. Patent No. ‘397 (see col. 343, claim 17, example 2-2, col. 243, lines 33-41 for HCl salt) and its method of use as recited in the instant claims (see col. 9, lines 30-40). Claims 81-86 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 10,597,377. Although the claims at issue are not identical, they are not patentably distinct for the reasons set forth in U.S. Patent No. 11,414,397 (more particularly the suggestion of employing the HCl salt in the claimed method). Claims 81-86 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 10,875,839. Although the claims at issue are not identical, they are not patentably distinct for the reasons set forth in U.S. Patent No. 11,414,397 (more particularly the suggestion of employing the HCl salt in the claimed method). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 81-86 are rejected under 35 U.S.C. 102(a)(2) as being anticipated over Zhao et al. [U.S Patent No. 10,597,377-mentioned in IDS]. The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. The instantly claimed invention is taught. At column 260, lines 54-56, see the units for oral administration. At column 263, lines 48-60, see the guidance for dosing administration. The reference teaches the typical range of 0.01mg -2000 mg per day for adult human treatment. At column 341, see claim 4. The claim is reproduced below: PNG media_image2.png 418 668 media_image2.png Greyscale and HCl salts recited at col. 237, lines 35-41. PNG media_image3.png 384 660 media_image3.png Greyscale (see claim 6 for neuroendocrine tumor treatment as well). Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Feb 26, 2024
Application Filed
Jul 09, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT
Oct 08, 2026
Examiner Interview (Telephonic)
Oct 08, 2026
Examiner Interview Summary
Oct 08, 2026
Response Filed
Nov 05, 2026
Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799081
MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS THEREOF
2y 10m to grant Granted Nov 17, 2026
Patent 12788736
TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS
4y 8m to grant Granted Nov 10, 2026
Patent 12790318
PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD
3y 8m to grant Granted Nov 10, 2026
Patent 12790317
RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF
2y 11m to grant Granted Nov 10, 2026
Patent 12753196
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
3y 6m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.4%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1145 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month